The discovery of SKLB-0335 as a paralog-selective EZH2 covalent inhibitor

被引：14

作者：

Zhang, Qiangsheng ^{[1
]}

Hu, Xi ^{[1
]}

Li, Lu ^{[2
]}

Zhang, Lidan ^{[1
]}

Wan, Guoquan ^{[1
]}

Feng, Qiang ^{[3
]}

Zhu, Yongxia ^{[4
]}

Wang, Ningyu ^{[5
]}

Liu, Zhihao ^{[1
]}

Yu, Luoting ^{[1
]}

机构：

[1] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, West China Med Sch,Collaborat Innovat Ctr Biother, Chengdu 610041, Sichuan, Peoples R China

[2] Sichuan Univ, West China Hosp, Inst Clin Trials, Chengdu 610041, Sichuan, Peoples R China

[3] Chengdu Normal Univ, Coll Chem & Life Sci, Chengdu 611130, Peoples R China

[4] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Dept Clin Pharm, Chengdu 610041, Peoples R China

[5] Southwest JiaoTong Univ, Sch Life Sci & Engn, Chengdu 611756, Sichuan, Peoples R China

来源：

CHEMICAL COMMUNICATIONS | 2021年 / 57卷 / 24期

基金：

中国国家自然科学基金;

关键词：

D O I：

10.1039/d0cc04670a

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

By targeting the unique Cys663 of EZH2, SKLB-0335 displays high paralog-selectivity on EZH2. Biochemical studies show that SKLB-0335 can covalently bind to EZH2 at its S-adenosylmethionine (SAM) pocket and inhibit H3K27Me3. SKLB-0335 could be an effective chemical probe with which to further investigate the specific biological functions of EZH2.

引用

页码：3006 / 3009

页数：4

共 50 条

[31] SAH derived potent and selective EZH2 inhibitors
Kung, Pei-Pei
Huang, Buwen
Zehnder, Luke
Tatlock, John
Bingham, Patrick
Krivacic, Cody
Gajiwala, Ketan
Diehl, Wade
Yu, Xiu
Maegley, Karen A.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (07) : 1532 - 1537
[32] Pharmacological inhibition of EZH2 using a covalent inhibitor suppresses human ovarian cancer cell migration and invasion
Lihong Shi
Qiangsheng Zhang
Shirui Zhu
Qing Tang
Xin Chen
Rui Lan
Ningyu Wang
Yongxia Zhu
Molecular and Cellular Biochemistry, 2024, 479 : 831 - 841
[33] Discovery of novel bicyclic pyridone derivatives as inhibitors of EZH2
Marx, Marx
Bobinski, Thomas
Briere, David
Christensen, James
Galemmo, Robert
Lee, Matthew
Sudhakar, Niranjan
Winkelman, Jeff
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 255
[34] Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding
Que, Nanette L. S.
Crowley, Vincent M.
Duerfeldt, Adam S.
Zhao, Jinbo
Kent, Caitlin N.
Blagg, Brian S. J.
Gewirth, Daniel T.
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (07) : 2793 - 2805
[35] Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2
Velez, Julia
Dale, Brandon
Park, Kwang-Su
Kaniskan, H. Umit
Yu, Xufen
Jin, Jian
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 267
[36] Selective inhibition of EZH2 by a small molecule inhibitor regulates microglial gene expression essential for inflammation
Arifuzzaman, Sarder
Das, Amitabh
Kim, Sun Hwa
Yoon, Taeho
Lee, Young Seek
Jung, Kyoung Hwa
Chai, Young Gyu
BIOCHEMICAL PHARMACOLOGY, 2017, 137 : 61 - 80
[37] Identification of molecules that regulate the sensitivity of EZH2 inhibitor in neuroblastoma
Endo, Yuki
Takenobu, Hisanori
Sugino, Ryuichi
Haruta, Masayuki
Mukae, Kyosuke
Satoh, Shunpei
Shinno, Yoshitaka
Hasegawa, Mariko
Okada, Ryu
Katai, Yutaka
Nio, Masaki
Ohira, Miki
Kamijo, Takehiko
CANCER SCIENCE, 2018, 109 : 1176 - 1176
[38] First EZH2 Inhibitor Approved-for Rare Sarcoma
Leslie, Mitch
CANCER DISCOVERY, 2020, 10 (03) : 333 - 334
[39] THE EZH2 INHIBITOR TAZEMETOSTAT SHOWS EFFICACY IN FOLLICULAR LYMPHOMA
不详
CANCER DISCOVERY, 2020, 10 (12) : 1787 - 1787
[40] Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2
Patel, Pallav D.
Yan, Pengrong
Seidler, Paul M.
Patel, Hardik J.
Sun, Weilin
Yang, Chenghua
Que, Nanette S.
Taldone, Tony
Finotti, Paola
Stephani, Ralph A.
Gewirth, Daniel T.
Chiosis, Gabriela
NATURE CHEMICAL BIOLOGY, 2013, 9 (11) : 677 - +

← 1 2 3 4 5 →